About the Global CEO Initiative on Alzheimer’s Disease
The Global CEO Initiative on Alzheimer’s Disease (CEOi) is convened by UsAgainstAlzheimer's and is a collaboration of leading private sector organizations dedicated to accelerating progress in the fight against Alzheimer's disease.
Innovation is essential, but outcomes are shaped by coorination, clarity, and a shared commitment across the ecosystem.
By leveraging the collective influence of its memebers, CEOi works to shape global dialogue, drive innovations in diagnostics and treatment, and increase global awareness of Alzheimer's.
CEOi's Two Priorities: Detection & Diagnosis and Prevention & Preclinical
Enable market readiness for diagnostic and care innovations around the world
Advance global prevention strategies and promote access to affordable detection, diagnosis, and treatment
Our Areas of Action
Convening & Consensus
Unite global experts to advance consensus-driven strategies that promote brain health, advance prevention, and accelerate market readiness for diagnostics.
Education & Awareness
Forge collaborative partnerships to deliver impactful education and communications campaigns that promote Alzheimer’s innovations and expand access.
Advocacy & Problem Solving
Actively engage with members and partners to identify key challenges and opportunities in the Alzheimer’s space to drive solutions for global impact.
Collaborative Workgroups Pushing Alzheimer’s Diagnostic Knowledge Forward
BBM Workgroup
Our Mission
To prepare for the widespread adoption of blood-based biomarkers in clinical practice to enable a more simple, timely, and accurate diagnostic experience for patients.
90+ Participants
The BBM Workgroup attracted more than 90 participants, including experts from healthcare, academia, non-profit, government, venture capital, industry, and patient advocacy.
DCA Workgroup
Our Mission
To prepare for the adoption of digital cognitive assessments in clinical care so patients experience a more simple, timely, and accurate diagnostic experience
200+ Participants
The DCA Workgroup attracted more than 200 participants with a diverse array of backgrounds, including experts from health systems, academia, industry, digital health, diagnostic vendor organizations, patient advocacy, and payers.
